SION-451 + SION-2222 + SION-109 + Placebo SION-451 + Placebo SION-2222 + Placebo SION-109
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis (CF)
Conditions
Cystic Fibrosis (CF)
Trial Timeline
Jul 23, 2025 → Jun 1, 2026
NCT ID
NCT07035990About SION-451 + SION-2222 + SION-109 + Placebo SION-451 + Placebo SION-2222 + Placebo SION-109
SION-451 + SION-2222 + SION-109 + Placebo SION-451 + Placebo SION-2222 + Placebo SION-109 is a phase 1 stage product being developed by Sionna Therapeutics for Cystic Fibrosis (CF). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07035990. Target conditions include Cystic Fibrosis (CF).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07035990 | Phase 1 | Recruiting |
Competing Products
20 competing products in Cystic Fibrosis (CF)